AURORA CANNABIS INC
ACB · Medicinal Chemicals & Botanical Products · EDGAR filings ↗
Grade
C61Cannabis producer that screens high versus a money-losing peer set but is only barely profitable in absolute terms.
Strengths
- Strong liquidity: current ratio 4.3 (86th pct), low debt (D/E 55.6th pct)
- Gross margin 55% (76.5th pct) and finally GAAP-positive after years of losses
Risks
- Near-zero absolute returns (ROE 0.26%, net margin 0.46%) and interest coverage 0.59 (<1x)
- Winding down the consumer business; reliant on shelf/ATM capital raises
- High percentiles reflect a distressed peer group, not genuine strength
Notable findings
- No interest coverageInterest coverage 0.59 (cannot cover interest)
- Notable holderHeld by 3 notable fund(s): GOLDMAN SACHS GROUP INC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC (as of 2026-03-31)
Key metrics
Gross margin
54.6%
Operating margin
1.4%
Net margin
0.5%
Return on equity
0.3%
Return on assets
0.2%
ROIC
0.6%
Debt / equity
0.1×
Interest coverage
0.6×
Current ratio
4.3×
Tangible book value
$394M
Cash & investments
$96M
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT03522467 ↗ | Cannabis Oil for Pain Effectiveness Cancer, Chronic Pain | PHASE2 | Unknown | 2020-06-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 40-F | 2026-06-11 | 2026-03-31 | 0001628280-26-042364 ↗ |
| 40-F | 2025-06-18 | 2025-03-31 | 0001683541-25-000008 ↗ |
| 40-F | 2024-06-20 | 2024-03-31 | 0001683541-24-000009 ↗ |
| 40-F | 2023-06-14 | 2023-03-31 | 0001683541-23-000007 ↗ |
| 40-F | 2022-09-21 | 2022-06-30 | 0001683541-22-000002 ↗ |
| 40-F | 2021-09-27 | 2021-06-30 | 0001683541-21-000003 ↗ |
| 40-F | 2020-09-25 | 2020-06-30 | 0001628280-20-013898 ↗ |
| 40-F | 2019-09-11 | 2019-06-30 | 0001683541-19-000008 ↗ |